Rieger Jayson 4

4 · Verrica Pharmaceuticals Inc. · Filed Nov 25, 2025

Form 4

Period: 2025-11-25

DirectorCEO and President

Transactions

Purchase
Series C Warrant (right to buy)
2025-11-25+23,577→ 23,577 total
Exercise: $6.32Exp: 2030-11-25→ Common Stock (23,577 underlying)
Purchase
Common Stock
2025-11-25$4.24/sh+94,311$400,114→ 182,593 total

Holdings

Footnotes (4)

[F1]Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.
[F2]These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
[F3]Immediately exercisable.
[F4]The reported securities are included within 94,311 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

Documents

1 file